Impact of Conditioning Regimen on Outcomes for XXXX with @entity706 Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation.

@entity1 @entity1733 @entity706 @entity358 @entity348 @entity1893 @entity34
UNASSIGNED: There are limited data to guide the choice of @entity34 ( @entity34 ) regimen before autologous hematopoietic cell transplantation (AHCT) for @entity1 with Hodgkin ( @entity1733 ) and @entity1893 ( @entity1893 ). We studied 4917 @entity1 ( @entity1893 , n  = 3905; @entity1733 , n  = 1012) who underwent AHCT from 1995 to 2008 using the most common @entity34 platforms: carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) (n  = 1730); cyclophosphamide, BCNU, and etoposide (CBV) (n  = 1853); busulfan and cyclophosphamide (BuCy) (n  = 789); and @entity348 ( @entity348 )-containing treatment (n  = 545). CBV was divided into CBV(high) and CBV(low) based on BCNU dose. We analyzed the impact of regimen on development of @entity358 ( @entity358 ), transplantation-related mortality (TRM), and progression-free and overall survival. The 1-year incidence of @entity358 was 3% to 6% and was highest in recipients of CBV(high) (hazard ratio [HR], 1.9) and @entity348 (HR, 2.0) compared with BEAM. One-year TRM was 4% to 8%, respectively, and was similar between regimens. Among @entity1 with @entity1893 , there was a significant interaction between histology, @entity34 regimen, and outcome. Compared with BEAM, CBV(low) (HR, .63) was associated with lower mortality in @entity706 (P < .001), and CBV(high) (HR, 1.44) was associated with higher mortality in diffuse large B cell lymphoma (P  = .001). For @entity1 with @entity1733 , CBV(high) (HR, 1.54), CBV(low) (HR, 1.53), BuCy (HR, 1.77), and @entity348 (HR, 3.39) were associated with higher mortality compared with BEAM (P < .001). The impact of specific AHCT regimen on post-transplantation survival is different depending on histology; therefore, further studies are required to define the best regimen for specific diseases.
